Nama's AI scorecard currently rates Hims & Hers Health Sell (3.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does HIMS report earnings?

Hims & Hers Health's next scheduled report is on Nov 9, 2026. Analysts expect EPS of $0.06.

What is the HIMS price target?

The median analyst price target from 13 analysts is $31.00, with a range of $23.00 – $42.00.

Is HIMS Shariah compliant?

Nama's AAOIFI-style screen reads Hims & Hers Health as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Hims & Hers Health (HIMS)

Healthcare · Drug Manufacturers Specialty Generic · NYSE

Hims & Hers Health (HIMS) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $6.07B and a free-cash-flow yield of 0.8%. Over the most recent reported fiscal year, revenue grew 59.0% and free cash flow per share fell 73.5%. Nama's AI scorecard rates it Sell, 3.2 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Sell · 3.2/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Lagging · -28.9% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-64.4%

How far the last close sits under the highest price of the past five years.

Market cap	$6.07B
Trailing P/E	—
Price / book	18.7
Price / sales	2.4
FCF yield	0.8%
Dividend yield	—
Gross margin	68.4%
Operating margin	-6.0%
Net margin	-5.5%
Revenue growth (YoY)	+59.0%
Revenue growth (3-yr annual)	+64.5%
EPS growth (YoY)	+16.3%
FCF/share growth (YoY)	-73.5%
Beta	2.4
Exchange	NYSE
Sector	Healthcare
Industry	Drug Manufacturers Specialty Generic

HIMS earnings

Next report: Nov 9, 2026 (Q3 2026, EPS estimate $0.06). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 10, 2026	-$0.37	-$0.05	-640.0%	$753.21M
Q1 2026	May 11, 2026	-$0.19	$0.13	-246.2%	$608.10M
Q4 2025	Feb 23, 2026	$0.22	$0.19	+15.8%	$617.82M
Q3 2025	Nov 3, 2025	$0.28	$0.23	+21.7%	$598.98M

HIMS analyst price target

Median target $31.00 from 13 analysts, ranging $23.00 – $42.00.

Drug Manufacturers Specialty Generic peers

Ticker	Company	Market cap	P/E
TAK	Takeda Pharmaceutical	$67.16B	42.0
TEVA	Teva Pharmaceutical Industries	$49.72B	18.0
HLN	Haleon	$40.17B	21.3
ZTS	Zoetis	$32.81B	12.0
UTHR	United Therapeutics	$23.94B	21.2
VTRS	Viatris	$22.87B	7.8
NBIX	Neurocrine Biosciences	$16.66B	16.5
ELAN	Elanco Animal Health	$12.86B	24.3

Explore live HIMS data on Nama Insights →

Recent Congressional trades

Hims & Hers Health trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Lisa McClain	House	Buy	$1,001 - $15,000	Sep 12, 2025

HIMS FAQ

Is HIMS a buy?: Nama's AI scorecard currently rates Hims & Hers Health Sell (3.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does HIMS report earnings?: Hims & Hers Health's next scheduled report is on Nov 9, 2026. Analysts expect EPS of $0.06.
What is the HIMS price target?: The median analyst price target from 13 analysts is $31.00, with a range of $23.00 – $42.00.
Is HIMS Shariah compliant?: Nama's AAOIFI-style screen reads Hims & Hers Health as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.